When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Hypertriglyceridemia

Last reviewed: 22 Nov 2024
Last updated: 29 Nov 2024

Summary

Definition

History and exam

Key diagnostic factors

  • eruptive xanthomas
  • lipemia retinalis
Full details

Other diagnostic factors

  • increased BMI/waist circumference
  • lipodystrophy
  • features of coronary artery disease
  • claudication
  • neurologic features
  • recurrent abdominal pain
Full details

Risk factors

  • family history of hyperlipidemia
  • high saturated fat diet
  • high carbohydrate or high glycemic index diet
  • excessive alcohol consumption
  • family or personal history of overweight/obesity
  • family or personal history of diabetes
  • insulin resistance
  • liver disease
  • renal disease
  • HIV infection
  • medications
  • Cushing syndrome
  • inflammatory/immune disorders
  • organ transplant
  • hypothyroidism
  • pregnancy
Full details

Diagnostic tests

1st tests to order

  • triglyceride level
Full details

Tests to consider

  • apolipoprotein B
  • fasting plasma glucose
  • BUN, creatinine
  • urinary albumin/protein
  • serum albumin
  • thyroid-stimulating hormone
  • liver function tests
  • C-reactive protein
Full details

Treatment algorithm

ACUTE

chylomicronemia

ONGOING

moderate HTG (fasting TG ≥150 mg/dL [≥1.7 mmol/L] or nonfasting TG ≥175 mg/dL [≥2.0 mmol/L] and TG <500 mg/dL [<5.6 mmol/L])

severe HTG (fasting TG ≥500 mg/dL [≥5.6 mmol/L] especially fasting TG ≥1000 mg/dL [≥11.3 mmol/L])

Contributors

Authors

Robert A. Hegele, MD, FRCPC, Cert Endo, FACP, FAHA

Jacob J. Wolfe Distinguished Medical Research Chair

Martha Blackburn Chair in Cardiovascular Research

Distinguished University Professor of Medicine and Biochemistry

University of Western Ontario

London

Ontario

Canada

Disclosures

RAH reports consulting fees from Acasti, Aegerion, Akcea/Ionis, Amgen, Boston Heart, HLS Therapeutics, Novartis, Pfizer, Regeneron, Sanofi and UltraGenyx. RAH is an author of references cited in this topic.

Acknowledgements

Dr Robert A. Hegele would like to gratefully acknowledge Dr David Alexander Leaf, the previous contributor to this topic.

Disclosures

DAL declares that he has no competing interests.

Peer reviewers

Vinaya Simha, MBBS, MD

Associate Professor

Mayo Clinic

Rochester

MN

Disclosures

VS declares that he has no competing interests.

  • Hypertriglyceridemia images
  • Differentials

    • Diabetes
    • Lipodystrophies
    • Liver disease
    More Differentials
  • Guidelines

    • Guidelines for the primary prevention of stroke
    • Cardiovascular disease: risk assessment and reduction, including lipid modification​​
    More Guidelines
  • Patient information

    High cholesterol

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer